A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.
In light of the recurrent outbreaks of low pathogenic avian influenza (LPAI) and highly pathogenic avian influenza (HPAI), there is a pressing need for the development of vaccines that allow rapid mass vaccination. In this study, we introduced by reverse genetics temperature-sensitive mutations in the PB1 and PB2 genes of an avian influenza virus, A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) (WF10). Further genetic modifications were introduced into the PB1 gene to enhance the attenuated (att) phenotype of the virus in vivo. Using the att WF10 as a backbone, we substituted neuraminidase (NA) for hemagglutinin (HA) for vaccine purposes. In chickens, a vaccination scheme consisting of a single dose of an att H7N2 vaccine virus at 2 weeks of age and subsequent challenge with the wild-type H7N2 LPAI virus resulted in complete protection. We further extended our vaccination strategy against the HPAI H5N1. In this case, we reconstituted an att H5N1 vaccine virus, whose HA and NA genes were derived from an Asian H5N1 virus. A single-dose immunization in ovo with the att H5N1 vaccine virus in 18-day-old chicken embryos resulted in more than 60% protection for 4-week-old chickens and 100% protection for 9- to 12-week-old chickens. Boosting at 2 weeks posthatching provided 100% protection against challenge with the HPAI H5N1 virus for chickens as young as 4 weeks old, with undetectable virus shedding postchallenge. Our results highlight the potential of live att avian influenza vaccines for mass vaccination in poultry.
Song
Haichen
H
Department of Veterinary Medicine, University of Maryland, College Park, MD 20742-3711, USA.
Nieto
Gloria Ramirez
GR
Perez
Daniel R
DR
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D002642:Chick Embryo; D002645:Chickens; D004285:Dogs; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D053127:Influenza A Virus, H9N2 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D005585:Influenza in Birds / Q000517:prevention & control*; D009154:Mutation; D009439:Neuraminidase / Q000235:genetics; D010641:Phenotype; D013047:Specific Pathogen-Free Organisms; D016019:Survival Analysis; D014132:Trachea / Q000821:virology; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D014764:Viral Proteins / Q000235:genetics
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; C502893:PB2 protein, influenza virus; D014613:Vaccines, Attenuated; D014764:Viral Proteins; C109963:hemagglutinin, avian influenza A virus; C077346:influenza virus polymerase basic protein 1; D009439:Neuraminidase